Table 3.
Association of baseline CTCs and cfDNA with best response to nivolumab.
| Best Response | ||||||||
|---|---|---|---|---|---|---|---|---|
| Baseline Biomarkers | Partial Response-Stable Disease | Progressive Disease | Total | OR | 95% CI | p-Value | ||
| N | % | N | % | N | ||||
| CTCs | ||||||||
| ≤2 | 16 | 41 | 23 | 59 | 39 | 1 | (Ref.) | 0.405 |
| >2 | 14 | 52 | 13 | 48 | 27 | 0.62 | 0.20–1.92 | |
| cfDNA | ||||||||
| ≤836.5 | 14 | 38 | 23 | 62 | 37 | 1 | (Ref.) | 0.191 |
| >836.5 | 16 | 55 | 13 | 45 | 29 | 0.48 | 0.16–1.45 | |
Association was estimated through a multinomial logistic regression modelling using the median values of 2 CTCs and 836.5 ng cfDNA as cutoff points. OR: odds ratio adjusted for age at start of nivolumab, gender, histotype, ECOG PS, smoking status, number of metastases, prior lines of treatment; 95% confidence intervals for OR. p-value: probability level associated with the likelihood ratio test. Ref.: reference category.